Request ConsultationCall
Chicago breast augmentation banner with implant

Implant Recall: What You Should Know

Notes on the textured implant recall

In late July, Allergan began the process of recalling Biocell Textured Implants from the market. They are recalling implants that have not been placed; the FDA does not recommend removing implants from patients who are not experiencing symptoms of Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). It is estimated that only 1 in 2,207 patients (0.04%) with the recalled Biocell Textured Implants will develop BIA-ALCL in their lifetime.

ALCL is a type non-Hodgkin’s Lymphoma, a cancer of immune cells. BIA-ALCL is newly designated type of the disease that forms in the scar tissue surrounding the implant. So far, BIA-ALCL has only been detected in patients who have or have had textured breast implants. To date, no one with SMOOTH breast implants has developed BIA-ALCL. The disease itself is considered very treatable, with patients being cured by simply removing the implants and surrounding scar tissue. Currently, 93% of BIA-ALCL patients are disease free at 3 years.

BIA-ALCL in Perspective

  • 1 in 3 Americans will develop a form of cancer in their lifetime.
  • 1 in 8 women will develop breast cancer in their lifetime.
  • 573 cases of BIA-ALCL have been confirmed out an estimated 35 million patients with textured implants, or 1 in 61,082.

The Geldner Center has reached out to our patients who had/have the recalled implants. If you’d like to know the type of implant you have, we encourage you to contact us. If you’d like to know more about BIA-ALCL and the symptoms, please visit the FDA or the ASPS website for the most up to date information.

"*" indicates required fields

Want to learn more?